
Our Partnership
Key Structures
Topics
Results & Data
Impact Stories
Twelve-year-old Francis’ Heroic Fight Against Drug-resistant Tuberculosis
Krayé’s Fight: Protecting His Community and Future Generations Against Malaria
Spotlight on Health Workers Fighting HIV in Sri Lanka
Asad’s Fight: Surviving Tuberculosis Under the Threat of COVID-19
News Releases
Global Fund Board Calls for Global Mobilization Ahead of Crucial Seventh Repleni…
Global Fund Thanks European Union and Team Europe for Their Contribution to COVI…
Global Fund Applauds New Zealand’s Commitment to COVID-19 Response Mechanism
Global Fund, United States and Unitaid Launch “Test-and-Treat” Programs at Secon…
Opinion
Ukrainian LGBTI Activist on Breaking Down Barriers to Health Despite Deadly Conf…
The Pivotal Role the Private Sector Can Play in Fight Against TB
Fighting AIDS and COVID-19 Depend on a Firm Foundation
Data Agility: A Fashionable Term, or a Game Changer for Global Health?
Updates
Featured
The Global Fund’s quality assurance information notices provide guidance and advice on how to operationalize in practical terms the consequences of a quality or a safety issue related to a product that has been procured with Global Fund funds. The initial information, stated in the notice, comes from the manufacturer of health products in question and/or is confirmed by stringent regulatory mechanisms.
Information Notices29
The QA information notice 2022-01 has been withdrawn. All additional QC testing results comply with standards and therefore the potential quality issue has not been confirmed for the Artesunate powder for injection 60mg manufactured and commercialized by IPCA
The Global Fund uses cookies for anonymized statistics on website use and content performance to help us improve and adapt the website. To consent to the use of cookies, please click “Accept”. To learn more about your rights and options, please read our Privacy Statement.